Keith Hoffman Joins HepQuant as Clinical Lab Manager
Brings more than 20 years of pharmaceutical industry experience in LC/MS analytics and lab management
DENVER (Feb. 20, 2019) — HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced the addition of Keith Hoffman as Clinical Lab Manager.
Mr. Hoffman joins HepQuant with more than 20 years of pharmaceutical industry experience in liquid chromatography/mass spectrometry (LC/MS) analytical method development and lab management. In this role at HepQuant, Mr. Hoffman is responsible for evaluating lab performance including test cycle time, capacity, throughput, and quality.
“Keith is respected in the industry for his immense LC/MS knowledge and lab performance optimization,” noted Rick Whitcomb, Chief Operating Officer of HepQuant. “He brings added depth and leadership to our lab operations as we expand our footprint with liver disease research sites and pharmaceutical companies with liver disease therapies in development.”
Most recently, Mr. Hoffman served as Laboratory Manager at AmeriDrug Laboratories where he managed laboratory operations. From 2009-2016, he was Research Instructor/ MS Laboratory Manager at the University of Colorado where he oversaw and managed laboratory operations for 15 scientists and 10 mass spectrometers.
Prior to joining CU, he held various research scientist roles at Array Biopharma and Pfizer, focusing on research related to pharmacokinetics and drug metabolism. He also worked as a research chemist at Wisconsin Analytical and Research Services, and as a chemist at Wisconsin Hazleton Laboratories America.
A member of the American Society of Mass Spectrometry American Association of Pharmaceutical Scientist (AAPS), Mr. Hoffman has co-authored numerous scientific research publications. He holds a B.S. Biology / Chemistry from the University of Wisconsin-Whitewater.
Headquartered in Greenwood Village, Colorado, HepQuant, LLC, is a privately-held, early-stage combination drug and in-vitro diagnostic company. HepQuant’s products are investigational combination drug and in-vitro diagnostic devices and have not yet been evaluated or reviewed by the US Food and Drug Administration (FDA) for commercial sale. They are currently available for investigational use via the FDA IDE application process. For additional information, visit www.hepquant.com.
Sean Bundy | Director of Regulatory and Quality Affairs | [email protected]
Bradley C. Everson | Chief Business Development Officer | [email protected]